Houston-based Data Gumbo, an industrial blockchain-software-as-a-service company, announced that its latest round or funding. Photo courtesy of Data Gumbo

Data Gumbo, a Houston-based tech startup, has picked up $4 million in a series C round from the venture capital arms of foreign energy companies Saudi Aramco and Equinor.

The funding for Data Gumbo came from Saudi Aramco Energy Ventures, the VC subsidiary of government-owned oil and natural gas giant Saudi Aramco, and Equinor Technology Ventures, the VC subsidiary of Norwegian energy operator Equinor. The U.S. headquarters for both Saudi Aramco and Equinor are in Houston.

Data Gumbo said in January that it had signed up Equinor as a customer.

Only last year, Data Gumbo announced it had raised a $7.7 million series B round with participation by Saudi Aramco, Equinor Technology Ventures, and VC and private equity firm L37, which has an office in Houston. The startup has hauled in $26.7 million in funding since its founding in 2016, according to Crunchbase.

Data Gumbo provides a contract platform, GumboNet, that is powered by blockchain technology. The platform serves more than 180 corporate customers in the oil and gas sector. The startup says the funding will enable it to expand its contract automation offering beyond the energy industry.

“While we started in energy, we already have value for bulk commodity haulage, trucking and shipping, with plans to parlay our momentum into other global industries,” says Andrew Bruce, founder and former CEO of Data Gumbo. “Wherever two or more organizations share a contractual relationship that can be verified with a digital source of data, opportunities abound to realize efficiencies and cost savings utilizing our blockchain network.”

Frank Andrasco, senior investment director at Saudi Aramco Energy Ventures, says Data Gumbo’s platform “has broad industrial applicability.”

The announcement of the $4 million funding round comes on the heels of William Fox being named CEO of Data Gumbo in July. Fox had been the startup’s chief product officer.

“The partnership with Equinor and Saudi Aramco, and their associated supply chains and partnerships, will continue the momentum for the Data Gumbo’s smart contract network,” Fox says.

Earlier this year, Data Gumbo announced the opening of an office in Saudi Arabia. Data Gumbo’s headquarters is at The Cannon’s coworking space in the Energy Corridor. It also maintains offices in Norway and the United Kingdom.

This week's roundup of Houston innovators includes Jim Sledzik of Saudi Aramco Energy Ventures, Arti Bhosale of Sieve Health, and Paul Cherukuri of Rice University. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from corporate venture capital to digital health — recently making headlines in Houston innovation.

Jim Sledzik, North American managing director of Saudi Aramco Energy Ventures

Jim Sledzik joins the Houston Innovators Podcast to discuss corporate venture, Houston's role in the energy transition, and more. Photo courtesy of Aramco

When it comes to venture capital, the corporate model can be considered a little less risky, Jim Sledzik, North American managing director of Saudi Aramco Energy Ventures, says on last week's episode of the Houston Innovators Podcast. Over the past decade, Saudi Aramco Energy Ventures has invested $320 million into 33 portfolio companies in the United States. Sledzik, who's worked in various energy services roles around the world before entering in to investment, explains that the corporate venture model is ideal for scaling big technology — and fast.

“When you’re using the venture model in a corporate setting, you have the company and the balance sheet behind you, which brings different benefits to companies you’re investing in,” he says. “These entrepreneurs who are looking to figure out how to deploy technology at scale becomes the real interesting item. All entrepreneurs want to grow — and they want to grow fast."

Scaling fast is risky, but big corporates — like Aramco — can help address the risks by providing a foothold in the market, a place to roll out the technology, and more. Click here to stream the episode and read more.

Arti Bhosale, co-founder and CEO of Sieve Health

Sieve Health is an AI cloud-based SaaS platform designed to automate and accelerate matching patients with clinical trials. Photo

Throughout her career, Arti Bhosale has seen the inefficiency and the ineffectiveness of selecting patients for clinical trials.

“Across the globe, more than 30 percent of clinical trials shut down as a result of not enrolling enough patients,” says Bhosale. “The remaining 80 percent never end up reaching their target enrollment and are shut down by the FDA.”

So, in 2020, Bhosale and her team developed Sieve Health, an AI cloud-based SaaS platform designed to automate and accelerate matching patients with clinical trials and increase access to clinical trials. Click here to read more.

Paul Cherukuri, the inaugural vice president for innovation at Rice University

Meet Paul Cherukuri — the new face of innovation at Rice University. Photo via Rice.edu

Rice University has stood up a new office of innovation — and named its new leader. Paul Cherukuri, the executive director of the Institute of Biosciences and Bioengineering, the inaugural vice president for innovation. In his role, Cherukuri will "lead Rice’s technology and commercialization infrastructure to translate breakthrough discoveries into inventions for the benefit of society," per a news release from Rice.

“I am thrilled and honored to serve in this new role at this inflection point in our university’s history,” Cherukuri says in the release. “Rice has some of the finest minds in the world and I look forward to working with President DesRoches and the leadership team he has assembled to chart a bold new path for world-changing innovation from Rice by engaging the remarkable innovation ecosystem including the Ion District, the Texas Medical Center, industry and other unique assets in Houston.” Click here to read more.

Jim Sledzik joins the Houston Innovators Podcast to discuss corporate venture, Houston's role in the energy transition, and more. Photo courtesy of Aramco

Houston corporate investor on why Houston is poised to lead the energy transition

HOUSTON INNOVATORS PODCAST EPISODE 145

When it comes to Houston's potential to lead the energy transition, Jim Sledzik, North American managing director of Saudi Aramco Energy Ventures, says it's a no-brainer.

"We understand the energy business — we understand size and scale. And the size and scale of the challenges in front of us to get to net zero is enormous,” he says on this week's episode of the Houston Innovators podcast. “The basics are here. We just need to tap into the talent and experience."

Over the past decade, Saudi Aramco Energy Ventures has invested $320 million into 33 portfolio companies in the United States. Sledzik, who's worked in various energy services roles around the world before entering in to investment, explains that the corporate venture model is ideal for scaling big technology — and fast.

“When you’re using the venture model in a corporate setting, you have the company and the balance sheet behind you, which brings different benefits to companies you’re investing in,” he says. “These entrepreneurs who are looking to figure out how to deploy technology at scale becomes the real interesting item. All entrepreneurs want to grow — and they want to grow fast."

Scaling fast is risky, but big corporates — like Aramco — can help address the risks by providing a foothold in the market, a place to roll out the technology, and more.

“With corporate venture, you can bring the assets and the application of those technologies, and you can work to scale it in a manner that’s somewhat derisked,” Sledzik says on the show. “In corporate venture capital, you have other levers in which to pull to add value to the entrepreneurs you’re investing in. The private side brings different values.”

Earlier this year, Aramco announced a partnership with the Ion, representing its dedication to the Houston innovation ecosystem. Sledzik says Aramco being named a founding partner at the Ion opens the door to more collisions with Houston entrepreneurs. Starting later this month, Sledzik and his team will host office hours every other Friday.

"Ion is the place where you can find those collisions,” he says. “You just never know when serendipity is going to be created.”

He shares more about the types of technology Aramco is looking for and his advice to energy tech entrepreneurs on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."